Yes, people do die from RSV. Globally, respiratory syncytial virus causes an estimated 160,000 deaths each year out of roughly 64 million infections. The vast majority of those deaths occur in two groups: very young children and older adults. For most healthy people, RSV feels like a bad cold and resolves on its own, but for vulnerable populations it can progress to life-threatening respiratory failure.
How Many People Die From RSV in the US
The CDC estimates that RSV kills between 100 and 300 children under age 5 in the United States each year, along with 6,000 to 10,000 adults aged 65 and older. Those numbers make RSV a more significant killer of older adults than many people realize. It also drives 58,000 to 80,000 pediatric hospitalizations and 60,000 to 160,000 hospitalizations among seniors annually.
Among otherwise healthy children who are hospitalized for RSV, the case fatality rate is low, around 0.2%. But the rate climbs sharply for children with underlying conditions. Kids with congenital heart disease who are hospitalized for severe RSV have a case fatality rate near 5.2%, and those with chronic lung disease face a rate around 4.1%. Premature infants fall somewhere in between, with a hospitalized case fatality rate averaging 1.2%.
How RSV Becomes Fatal
RSV doesn’t typically kill through the initial upper respiratory infection. The danger comes when the virus moves into the lower airways, triggering bronchiolitis (inflammation of the small airways) in infants or pneumonia in both children and adults. Swelling and mucus block airflow, and in severe cases the lungs can no longer exchange oxygen effectively. This progression to respiratory failure is the primary cause of death.
In adults, RSV also sets the stage for secondary bacterial pneumonia at alarmingly high rates. One large study comparing hospitalized adults with RSV to those with influenza found that 61.5% of RSV patients developed bacterial pneumonia, compared to 39.5% of flu patients. Acute kidney injury was also more common in the RSV group. Overall, hospitalized adults with RSV had a 10.1% in-hospital death rate, versus 5.5% for flu patients, making RSV roughly 52% more deadly than influenza once someone is sick enough to be admitted.
The highest risk period is the first month after symptoms appear. Research published in the Journal of Infectious Diseases found that more than 90% of respiratory or circulatory deaths occurring within one week of an RSV episode were directly attributable to the virus. That fraction dropped to about 80% for deaths occurring between one week and one month after illness. Beyond one month, the elevated risk fades.
Who Faces the Greatest Risk
Age is the single biggest risk factor, at both ends of life. Infants under 6 months old are especially vulnerable because their airways are tiny and their immune systems are immature. Premature babies face even higher risk. In very young infants, RSV can cause apnea, which means the baby stops breathing for stretches of 10 seconds or more.
At the other end of the spectrum, adults over 65 account for the large majority of RSV deaths in the US. Aging weakens the immune response and many older adults have conditions like heart failure or chronic lung disease that RSV can worsen dramatically. Even when RSV doesn’t directly cause death, it can destabilize these conditions enough to trigger fatal complications.
Children of any age with congenital heart disease, chronic lung conditions, or weakened immune systems also face significantly higher odds of severe illness. The same is true for adults who are immunocompromised, whether from medications, cancer treatment, or organ transplant.
Warning Signs That RSV Is Getting Serious
Most RSV infections start with a runny nose, cough, and mild fever. In infants, reduced feeding is often one of the earliest signs. The infection becomes concerning when breathing changes: look for wheezing, rapid breathing, visible effort with each breath (ribs pulling inward or nostrils flaring), or a bluish tint to the lips or fingernails. In babies under 6 months, pauses in breathing, unusual irritability, and significantly decreased activity are red flags.
In older adults, the shift from upper to lower respiratory symptoms, particularly increasing shortness of breath, persistent high fever, or confusion, signals that the infection may be progressing toward pneumonia or respiratory failure.
Prevention Tools That Reduce Deaths
Two RSV vaccines are now available for adults 60 and older. In clinical trials, a single dose of either vaccine prevented 75% to 84% of lower respiratory tract disease caused by RSV over two RSV seasons. Protection was strongest in the first season, with efficacy between 83% and 89%, then declined somewhat in the second year. The trials weren’t large enough to measure the effect on death directly, but preventing serious lung disease in older adults is expected to prevent a meaningful share of the thousands of annual deaths in this age group.
For infants, a long-acting antibody called nirsevimab (given as a single injection) has proven highly effective. In a CDC investigation across 27 hospitals, nirsevimab was 80% effective at preventing RSV-related ICU admission in infants during their first RSV season and 83% effective at preventing acute respiratory failure. Protection was strongest in the first two months after the dose (86% effective) and remained substantial through six months (66% effective). A separate option protects newborns through maternal vaccination: a dose given during pregnancy passes protective antibodies to the baby before birth.
These tools have changed the landscape considerably. RSV remains a serious virus, particularly for the very young and the very old, but the combination of infant antibody protection and adult vaccination means that many of the most severe outcomes, including death, are now preventable in ways they weren’t just a few years ago.